| abstract |
The present inventors have found that an HMGB1 fragment peptide having a specific amino acid sequence has an effect of suppressing finger adhesion and gastrointestinal scarring and an effect of prolonging survival time in a dystrophic epidermolysis bullosa model mouse. Was. Also, in a skin ulcer model, it was found that administration of the specific HMGB1 fragment peptide suppressed fibrosis of the skin during the ulcer healing process. Based on these findings, the present application provides a pharmaceutical composition for treating fibrotic diseases, comprising the specific HMGB1 fragment peptide. |